VR
Vertex Pharma
VRTX·NASDAQBoston MAFounded 198910,400 employees
Large CapbiotechPublicRare DiseaseGenetic Medicine
Platform: CFTR & Gene Edit
Market Cap
$120B
All Drugs
14
Clinical Trials
28
Failed / Terminated
7
FDA Approved
1
Stock Price & Catalysts (VRTX)
Loading VRTX stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Exagamglogene autotemcel | CTX001 | Approved | 4 | BCL11A | SCDThalassemia | ||
| Ivosotorasib | VRT-9022 | Preclinical | 1 | CD38 | RSVEwing Sarcoma | ||
| VRT-4938 | VRT-4938 | Preclinical | 2 | HER2 | Gastric CaPBC | ||
| VRT-5853 | VRT-5853 | Phase 3 | 2 | Aβ | NarcolepsyAML | ||
| Elrarapivir | VRT-3718 | NDA/BLA | 2 | PRMT5 | Rett | ||
| VRT-1891 | VRT-1891 | Phase 1 | 2 | KRASG12C | Heart FailureNSCLC | ||
| Sotosacituzumab | VRT-4359 | Phase 1 | 2 | MET | ALL | ||
| VRT-9481 | VRT-9481 | Phase 1/2 | 2 | Menin | ADPKDFabry | ||
| VRT-1576 | VRT-1576 | Phase 2/3 | 2 | RET | CholangiocarcinomaPSP | ||
| VRT-5441 | VRT-5441 | Phase 3 | 4 | GLP-1R | NB | ||
| Tixarelsin | VRT-130 | Phase 1 | 1 | ALK | Wilms | ||
| VRT-6833 | VRT-6833 | Preclinical | 1 | ALK | EoE | ||
| Zenotapinarof | VRT-4282 | Preclinical | 1 | CD38 | Cholangiocarcinoma | ||
| Adagratapinarof | VRT-1626 | Preclinical | 2 | BCMA | HSFabry |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (26)